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Abstract
Sepsis must be diagnosed quickly to avoid morbidity and mortality. However, the clinical
manifestations of sepsis are highly variable and emergency department (ED) clinicians
often must make rapid, impactful decisions before laboratory results are known. We previously developed a technique that allows the measurement of the biophysical properties of
white blood cells as they are stretched through a microfluidic channel. In this study we
describe and validate the resultant output as a model and score—the IntelliSep Index
(ISI)—that aids in the diagnosis of sepsis in patients with suspected or confirmed infection
from a single blood draw performed at the time of ED presentation. By applying this technique to a high acuity cohort with a 23.5% sepsis incidence (n = 307), we defined specific
metrics—the aspect ratio and visco-elastic inertial response—that are more sensitive than
cell size or cell count in predicting disease severity. The final model was trained and crossvalidated on the high acuity cohort, and the performance and generalizability of the model
was evaluated on a separate low acuity cohort with a 6.4% sepsis incidence (n = 94) and
healthy donors (n = 72). For easier clinical interpretation, the ISI is divided into three interpretation bands of Green, Yellow, and Red that correspond to increasing disease severity.
The ISI agreed with the diagnosis established by retrospective physician adjudication, and
accurately identified subjects with severe illness as measured by SOFA, APACHE-II, hospital-free days, and intensive care unit admission. Measured using routinely collected blood
samples, with a short run-time and no requirement for patient or laboratory information, the
ISI is well suited to aid ED clinicians in rapidly diagnosing sepsis.

Data Availability Statement: All relevant data are
within the manuscript and its Supporting
information files.
Funding: Cytovale, Inc. funded this research, in
part through grant support from Breakout Labs
(San Francisco, California) and the National
Science Foundation (IIP-1315895 and IIP1431033). Patient consent and medical direction
for the study was conducted independently at the
study facilities under the direction of Drs. Caffery,
Thomas, and O’Neal, who have no financial interest

Introduction
Sepsis is a serious and potentially life-threatening condition, and one of the leading causes of
death in the USA [1]. Most patients with suspected infection who are at risk of sepsis will present to the hospital via the emergency department (ED), where clinicians must diagnose sepsis
quickly and accurately in order to prioritize resources to care for those most at risk for clinical
deterioration [2]. Sepsis tends to progress very rapidly, and recent data suggests that each hour
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of delay to treatment results in an increase in morbidity and mortality [3, 4]. The rapid and
accurate diagnosis of sepsis is necessary for ED clinicians to quickly provide antibiotics and
resuscitation to the most acutely ill patients, while limiting broad spectrum antibiotic use in
less acutely-ill patients [5].
In practice, sepsis can be challenging to identify during an ED evaluation because the clinical manifestations of sepsis are highly variable [6]. Clinical criteria for systemic inflammatory
response syndrome, which previously served as a requisite for sepsis diagnosis, lack the sensitivity and specificity to accurately identify those patients most likely to progress to organ failure and death [7, 8]. The Third International Consensus Task Force has defined sepsis as “lifethreatening organ dysfunction due to a dysregulated host response to infection” and recommended that organ dysfunction be indicated by an increase in the Sequential Organ Failure
Assessment (SOFA) score of 2 points or more [9]. While this Sepsis-3 definition focuses on
patients with higher mortality risk, clinical data and laboratory results required for the calculation of SOFA may be unavailable or difficult to obtain in a timely manner [8]. As such, there is
a critical need for a rapid test that can aid ED clinicians in identifying sepsis among patients
with suspected or confirmed infection.
Inherent in the Sepsis-3 definition is the recognition that the patient’s immune system
becomes dysregulated in response to an infection, leading to aberrant immune activation and
subsequent clinical deterioration. In previous work, we developed a technique to rapidly quantify the state of immune activation by measuring the biophysical properties of white blood cells
(WBCs) [10–12]. By examining the physical changes that occur as cells are stretched through a
microfluidic channel, this approach provides label-free, quantitative biophysical markers of
immune activation. An earlier study demonstrated that this technique can rapidly characterize
thousands of single cells, and measure biophysical changes in subpopulations of WBCs that
are distinct in patients with sepsis [13].
In this study, we present the development and internal validation of a model and score—
the IntelliSep Index (ISI)–that aids in the diagnosis of sepsis in patients with suspected or confirmed infection. The model was trained and cross-validated with data from a high acuity
cohort, and data from a low acuity cohort and healthy volunteers were used to evaluate the
generalizability of the model and estimate its expected clinical performance. The robust performance of the model indicates that the ISI may be useful as an aid to ED clinicians in the rapid
and accurate diagnosis of sepsis.

Material and methods
Study design and setting
This work involved three prospective cohorts from separate studies—a high acuity cohort
(n = 307), a low acuity cohort (n = 94), and a healthy donor cohort (n = 72). The high acuity
cohort was used for feature generation and selection, and as a training set to derive the final
model reporting the ISI, whereas the low acuity cohort and the healthy donor cohort were
used to evaluate feature and model performance on new datasets. Peripheral blood samples
were collected from February 2016 to December 2016 for the high acuity cohort, and from July
2017 to January 2018 for the low acuity cohort, from subjects over 18 years of age who presented to the ED with signs suggestive of infection at two academic medical centers, namely
Our Lady of the Lake Regional Medical Center and Baton Rouge General Medical Center, in
Baton Rouge, LA. Subjects were identified for recruitment using the site’s electronic medical
records system. Blood samples for the healthy donor cohort were provided by Our Lady of the
Lake Blood Donor Center, Baton Rouge, LA, that collected blood from healthy volunteers who
donated blood between June 2018 and January 2020, and completed a questionnaire indicating

PLOS ONE | https://doi.org/10.1371/journal.pone.0246980 April 15, 2021

2 / 17

PLOS ONE

Validation of rapid cellular sepsis diagnostic

no current illnesses. All three studies were approved by the Louisiana State University Health
Sciences Center Institutional Review Board (IRB) as well as by local, hospital-specific IRBs as
appropriate (high acuity: Louisiana State University Health Sciences Center—New Orleans,
Human Subjects Research Protection Program and Institutional Review Board: LSUHSC-NO
#8964; low acuity: Louisiana State University Health Sciences Center—New Orleans, Human
Subjects Research Protection Program and Institutional Review Board: LSUHSC-NO #9749;
healthy: Franciscan Missionaries of Our Lady University Institutional Review Board: FRANU
#2018–022). The study team obtained written informed consent from all subjects. A detailed
flow chart for how we selected evaluable subjects in each cohort is presented in S1 Fig.
The high acuity cohort enrolled subjects with two or more criteria for Systemic Inflammatory
Response Syndrome (SIRS 2+) and at least one sign of potential organ dysfunction, defined as
serum lactate > 2 mmol/L, altered mental status, hypoxia (peripheral capillary oxygen
saturation < 90% on room air), hypotension (systolic blood pressure < 90 mmHg), acute kidney
injury, total bilirubin > 2.5 mg/dL, platelet count < 100,000 cells/μL, international normalized
ratio (INR) > 1.5 and no history of vitamin k antagonist use. The low acuity cohort enrolled
subjects with SIRS 2+ with or without evidence of organ dysfunction. Of note, the low acuity
cohort excluded abnormal WBC count from SIRS criteria in an effort to enroll subjects either
before laboratory data were available or those who did not have laboratory studies performed.
Subjects with hematologic malignancies, myeloproliferative diseases, and neutropenia
(absolute neutrophil count < 1000 cells /μL) were excluded. In addition, potential subjects
who were undergoing chemotherapy or with late-stage cancer, and those receiving macrolide
class antibiotics for greater than 3 hours prior to enrollment, were deemed non-evaluable and
were excluded from analysis. These subjects were excluded because of the unknown potential
effects of these conditions and medications on the biophysical properties of WBCs.
For all three studies, upon consent, an EDTA-anticoagulated peripheral blood sample was
obtained from the subject for the IntelliSep test and testing was performed on samples within
3 hours of sample blood collection.

Clinical classification of subjects
Pre-existing conditions and comorbidities were recorded using the subject’s medical record.
Diagnosis of infection (such as pneumonia) was obtained through retrospective adjudication
by physicians with access to the subject’s entire medical record, including results of tests, cultures, other lab tests per standard of care, and imaging results. For the determination of sepsis,
two independent physician adjudicators reviewed the subject’s medical record to assess
whether they had sepsis during the study as defined by the Sepsis-3 consensus guidelines (i.e.,
whether there is an infection present which caused a dysregulated immune response that led
to organ dysfunction) [8]. In cases of discordance, review of the subject’s medical record by a
third physician adjudicator was used to make the final determination.
Measures for clinical assessment included sequential organ failure assessment (SOFA)
scores [14], maximum over three days following ED presentation, acute physiology and
chronic health evaluation (APACHE-II) scores [15], and predisposition insult response and
organ failure (PIRO) scores [16]. Utilization of hospital resources was measured by admission
to the hospital, admission to the intensive care unit (ICU), in-hospital length of stay, excluding
days deceased while in-hospital (LOS), and ICU LOS.

IntelliSep test
Samples were evaluated using an early prototype version of the IntelliSep test (Cytovale, San
Francisco, CA). A 100 μL sample of EDTA-anticoagulated whole blood was incubated with
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5 μL PE-Cy5 CD45 (HI30 clone, Biolegend, cat. # 304010) and 5 μL of PE-CD66B (Becton
Dickinson, cat. # 561650) for 5 minutes. Red blood cells present in the sample were lysed using
the IMMUNOPREP Reagent System (Beckman Coulter) and red blood cell debris was washed
away using the Lyse Wash Assistant (BD Biosciences), resulting in a total volume of 1 mL of
WBCs suspended in PBS at a final concentration of 500–1000 cells/μL. The entire 1 mL of
WBC suspension was transferred to a cartridge that was then inserted into an imaging module
to interrogate single-cell biophysical properties via deformability cytometry [10–12]. A controlled pressure of 90 pounds per square inch (psi) was applied to push the WBC suspension
through the microfluidic channels, which contained an optical port to allow for high fidelity
imaging at the junction where the cells were deformed. Data were collected capturing cells
traveling through the microfluidic junction, yielding approximately 10–15 frames for each
deforming cell. The number of cells analyzed for each subject was 47,000 +/- 27,000 WBCs
(mean +/- SD), and the run-time for each test using a prototype system was approximately 30
minutes end-to-end, including sample processing and image analysis.
Quality checks were performed for each test run to ensure that the instrument was performing as intended, and control objects (8.86 μm, PS-COOH beads, microParticles GmbH) were
included in each sample to monitor the flow characteristics of the test run. Only test runs
where the trajectory of the control objects was consistent with an unobstructed extensional
flow region were accepted, while test runs in which the microfluidics were clogged were
excluded. The velocity of the control objects in a straight channel upstream of the junction was
also monitored to ensure that the target throughput was achieved. Other quality checks were
performed in each test run to monitor any drift or vibration in the instrument, as well as poor
lysis or wash performance during the sample preparation step.

Image analysis and metrics
All the steps in the image analysis pipeline were automated, from the raw video all the way to
the ISI, which was the final output. Images were analyzed by first passing the raw video (containing about 4 million frames) through an object detection algorithm to identify frames that
contain cells. Images from those frames were then passed through a convolutional neural network that segmented each image to distinguish the cell from the background. Descriptors of
cell shape, position, and morphology were computed for each image, and the metrics were
aggregated at the event level, where an event indicates an instance of a single cell travelling
through the extensional flow region. A primary metric, named visco-elastic inertial response
(VEIR), measures cell oscillations, which are dependent on cell density, size, and visco-elastic
properties. A secondary metric, termed aspect ratio (AR), quantifies the cell deformation
under hydrodynamic stress fields, which reflects nuclear compressibility. For clarity, the term
“metric” is used here to denote measures at the level of a single cell, whereas the term “feature”
denotes measures at the level of cell populations.
WBC subpopulations (lymphocytes, neutrophils, and monocytes) were identified and enumerated by measuring cell size and optical intensity, using an automated clustering algorithm.
The clustering algorithm was validated by comparing the cell clusters found by the automated
clustering, to the fluorescent data obtained from PE-Cy5 CD45 and PE-CD66B stains using
conventional flow cytometry techniques.
Once the metrics for each cell event were computed, and the cells segmented into subpopulations, statistical descriptors were computed to summarize the metrics into features. Some
example features include the average size of neutrophils and the 75th percentile of the VEIR of
monocytes. Finally, the ISI was computed by linearly combining all the features. Next, we
explain how the feature coefficients were determined during model training.
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Model training and validation
Only data from the high acuity cohort were used for model training (S1 Dataset). A cross-validation framework was used to train a linear logistic classifier to disease state (septic or not septic), using features as inputs. For classification, a logistic regression with a L1 regularization
available through scikit-learn’s sklearn.linear_model package was used. Scikit-learn is a free
and open-source Python library for data analysis and machine learning applications [17]. To
guard against over-fitting, data from approximately 25% of subjects in the high acuity cohort
were held out as a sequestered set for validation testing (sequestered testing set, n = 69). All of
the feature selection and model training was performed on a k-fold nested cross-validation
architecture on data from the remaining 75% of subjects (initial training set, n = 238). Once
the features were finalized, the model was validated using the sequester set to confirm the generalizability of the model development methodology.
The final model was generated by integrating the sequestered testing set into the initial
training set for a final training step, which included data from all of the subjects in the high
acuity cohort (full training set, n = 307). The ISI was produced by linearly transforming the
prediction from the final model in the log-odds space into a single score between 0.1 and 10.0,
inclusive. To allow for easier clinical interpretation, the range of the scores are divided into
three interpretation bands of Green (0.1–5.4), Yellow (5.5–6.7), and Red (6.8–10.0) that correspond to increasing probability of sepsis. The cutoffs for the interpretation bands were established based on observations from the full training set. Predictions of ISI using data from the
low acuity cohort and the healthy donor cohort were used to assess the performance and generalizability of the final model.

Statistical analysis
Unless otherwise stated, p-values were obtained from an unpaired two-sample Welch’s t-test
or Mann-Whitney U test, as appropriate, where the null hypothesis is that the mean of the two
samples are equal. Significance levels are indicated throughout the manuscript as follows: �
p < 0.05, �� p < 0.01, ��� p < 0.001. Descriptive statistics are presented as means, standard
deviations, medians, and interquartile ranges for the continuous variables, and as counts and
percentages for categorical variables. An alpha level of 0.05 was used for all analyses, unless
otherwise stated. Two-sided confidence intervals for proportions are provided using the Clopper-Pearson method, where appropriate. Two-sided confidence intervals for ROC AUC were
computed using a bootstrap method performed with 1000 replicates, where model predictions
on the test set were resampled with replacement to estimate a probability distribution for the
AUC. Time-to-event analyses are depicted with Kaplan-Meier plots, and the log-rank test was
used for comparison between groups.

Results
Subject demographics
The three separate prospective cohorts used for this work—a high acuity cohort, a low acuity
cohort, and a healthy donor cohort—represented a broad spectrum of potential disease severity. Baseline characteristics of the evaluable subjects from all three cohorts are presented in
Table 1. For the high acuity cohort, the median age was 62 years (Q1-Q3 50–74), with 153
male (49.8%) and 154 female (50.2%). Of the total, 53.1% were White, 40.1% were African
American, and 6.8% were members of other races. Median age was significantly lower for the
low acuity and healthy study populations at 55 (Q1-Q3 42–71) and 56 (Q1-Q3 38–68), respectively. Sex and race distributions for the low acuity and healthy studies were similar to the high
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Table 1. Baseline characteristics of subjects in each of the three cohorts.
Characteristic
Age, median (IQR)

High Acuity Cohort N = 307

Low Acuity Cohort N = 94

Healthy Donor Cohort N = 72

62.2 (50.4, 73.6) � , ⱡ

55.3 (42.3, 70.6) �

52.5 (38.0, 68.0) ⱡ

p-value(s)
�

p < 0.01

ⱡ p < 0.001
Sex, Female, N (%)

154 (50.2)

44 (46.8)

40 (55.6)

163 (53.1) �

47 (50.0) ⱡⱡ

63 (87.5) � , ⱡⱡ

�

NS

Race, N (%)
White

44 (44.8) ⱡⱡ

4 (5.6) , ⱡⱡ

21 (6.8)

3 (3.2)

3 (4.2)

Pulmonary

37 (12.0)

7 (7.4)

N/A

Genitourinary

24 (7.8)

4 (4.3)

N/A

African American
Other

123 (40.1)

�

�

p < 0.001

ⱡⱡ p < 0.001

Infection Source, N (%)

Skin-Skin Structure / Ortho / Wound

24 (7.8)

1 (1.1)

N/A

Abdominal / Gastrointestinal

23 (7.5)

4 (4.3)

N/A

Primary Bloodstream

9 (2.9)

2 (2.1)

N/A

Central Nervous System
Not Infected

1 (0.3)

0 (0.0)

N/A

197 (64.2) � , ⱡ

76 (80.9) � , ⱡⱡ

72 (100) ⱡⱡ, ⱡ

NS

�

p < 0.001

ⱡ p < 0.001
ⱡⱡ p < 0.001
Classification: Consensus RPD, N (%)
Sepsis

72 (23.5) �

6 (6.4) �

N/A

SIRS/Not Sepsis

235 (76.5) �

88 (93.6) �

N/A

Admitted to Hospital, N (%)

293 (95.4) �

65 (69.1) �

Admitted to ICU, N (%)

81 (26.4) �

11 (11.7)

4.0 (2.0, 6.0) �

2.0 (0.0, 4.0) �

0.0 (0.0, 1.0)

0.0 (0.0, 0.0)

N/A

31 (10.1) �

3 (3.2) �

N/A

Hospital LOS (days), median (IQR)
ICU LOS (days), median (IQR)
In-Hospital Mortality, N (%)
SOFA, 3-day max, median (IQR)
APACHE-II, median (IQR)
PIRO, median (IQR)
WBC (103 cells/μL), median (IQR)

4 (2, 5) �
15 (12, 19)

�

2 (0, 3) �
�

11 (8, 14)

�

�

p < 0.001

N/A

�

p < 0.001

N/A

�

p < 0.001

N/A

�

p < 0.001
NS

�

p < 0.01

N/A

�

p < 0.001

N/A

�

p < 0.001

5 (2, 7) �

3 (1, 4) �

N/A

�

p < 0.001

13.8 (10.1, 17.5) � , ⱡ

10.3 (7.5, 13.0) � , ⱡⱡ

6.0 (4.9, 7.0) ⱡⱡ, ⱡ

�

p < 0.001

ⱡ p < 0.001
ⱡⱡ p < 0.001
Triage Temperature, median (IQR)

98.2 (97.8, 98.7)

98.3 (98.0, 98.8)

N/A

NS

94.0 (81, 106)

99.5 (88, 109)

N/A

NS

Triage Respiratory Rate, median (IQR)

19 (17, 22)

20 (16, 23)

N/A

Lactate Measured, N (%)

212 (69.1) �

36 (38.3) �

N/A

Triage Heart Rate, median (IQR)

Lactate, median (IQR)
IntelliSep Index, median (IQR)

2.4 (1.5, 3.6)

1.9 (1.2, 2.9)

N/A

4.8 (3.7, 6.1) � , ⱡ

4.3 (3.4, 5.2) � , ⱡⱡ

2.2 (1.5, 3.2) ⱡⱡ, ⱡ

NS
�

p < 0.001
NS

�

p < 0.01

ⱡ p < 0.001
ⱡⱡ p < 0.001
Abbreviations: APACHE-II, acute physiology and chronic health evaluation; ICU, intensive care unit: IQR, interquartile range; LOS, length of stay; N/A, not applicable;
NS, not significant; PIRO, predisposition infection response organ; RPD, retrospective physician diagnosis; SOFA, sequential organ failure assessment; SIRS, systemic
inflammatory response syndrome; WBC, white blood cell count. p-values were obtained from an unpaired two-sample Welch’s t-test, with the null hypothesis that the
mean of the two samples are equal.
https://doi.org/10.1371/journal.pone.0246980.t001

acuity study, except for the significantly higher representation of While individuals in the
healthy cohort. As expected, the high acuity cohort had the highest rate of sepsis (23.5%) as
adjudicated by consensus retrospective physician review, which was significantly higher than
the 6% sepsis rate among the low acuity cohort (p< 0.001). The high acuity cohort also utilized
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more hospital resources (hospital admission, hospital length of stay, ICU admission), and had
greater severity of illness (higher SOFA, APACHE-II, and PIRO scores) and higher mortality
as compared to the low acuity cohort.

Feature performance
Representative scatter plots of cell size as compared to AR and VEIR for a healthy donor, a
subject adjudicated as non-septic SIRS 2+, and a subject adjudicated as septic are shown in Fig
1. For ease of interpretation, cells with high AR and high VEIR across all the scatters are
highlighted in red. The data show an increasing number of cells with high AR and high VEIR
corresponding to the adjudicated disease state of the subject—from healthy, to non-septic
SIRS 2+, to septic—indicating that AR and VEIR may characterize the immune activation
state of the measured leukocytes. Interestingly, cell size is not correlated with either AR or
VEIR, suggesting that additional information is provided by these measures. The data also
show that higher AR and higher VEIR lead to higher ISI values, and suggest that higher ISI values correlate with increasing levels of immune activation.
The performance of features in subjects with increasing severity of disease were further
explored by evaluating cell count, cell size, AR and VEIR for the entire population of healthy
donors as compared to subjects with SIRS 2+ and subjects with sepsis (Fig 2). The data show
statistically significant increases in cell count, cell size, AR, and VEIR of neutrophils and
monocytes for subjects with symptoms associated with increased immune activation. Specifically, mean neutrophil AR increased from 2.55 ± 0.24 (median ± SD) for the healthy donor
cohort to 3.13 ± 0.32 for septic subjects, and mean monocyte AR from 3.24 ± 0.37 to
3.42 ± 0.60, while mean neutrophil VEIR increased from 6.73 ± 0.60 μm to 8.19 ± 0.87 μm,
and mean monocyte VEIR from 8.26 ± 0.79 μm to 10.41 ± 0.90 μm. Trends for lymphocytes,
while statistically significant, appeared to be much weaker than those for neutrophils and
monocytes. Of note, cell size was not as sensitive as AR and VEIR in distinguishing disease status. This was particularly true for monocytes, where cell size was not statistically different
between healthy donors, subjects with SIRS 2+, or septic subjects, and hence was not as useful

Fig 1. Representative scatter plots of cell size versus aspect ratio and visco-elastic inertial focusing (VEIR) from a
healthy donor, a subject adjudicated as non-septic SIRS 2+ from the low acuity cohort, and a subject adjudicated
as septic from the high acuity cohort (S2 Dataset). As a visual aid, cells with high AR and high VEIR are hued in red.
For the purposes of this plot only, the cutoff for “high AR” was arbitrarily chosen as all the points defined by AR � 0.3
+ 2.5 x (Cell Size), and the cutoff for “high VEIR” was arbitrarily chosen as 9 μm.
https://doi.org/10.1371/journal.pone.0246980.g001
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Fig 2. Box plots displaying cell count, cell size, AR, and VEIR from healthy donors (n = 72), subjects with non-septic SIRS 2+ (n = 323), and
subjects with sepsis (n = 78), with features stratified by cell type (lymphocytes, neutrophils, and monocytes). For these experiments, data from
subjects presenting to the ED with 2 or more criteria for SIRS who were later adjudicated as non-septic or as septic were drawn from both the high
acuity and low acuity cohorts. Mean values were computed for each cell type within a single test run. A p-value < 0.001 was observed using one-way
analysis of variance for each feature for each cell type across the three cohorts, except for mean cell size for lymphocytes, where p-value was 0.002. The
p-value from a post-hoc unpaired Student’s two-sided t-test comparing two columns at a time are indicated as follows: � p < 0.05, �� p < 0.01, ���
p < 0.001, ���� p < 10−10. Box-plot elements: center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points,
outliers.
https://doi.org/10.1371/journal.pone.0246980.g002

as AR and VEIR in distinguishing sepsis. These observations are further supported by the
effect size as measured by Cohen’s d, shown in S1 Table.
Feature performance was further explored in subsets of healthy donors, subjects with SIRS
2+ and septic subjects that had normal WBC counts of 4x106 to 12x106 cells/mL (Fig 3).
Within this subset of subjects, WBC count alone, as is commonly provided by a complete
blood count (CBC), provides no indication of sepsis status. By comparison, both AR and VEIR
are markedly higher in septic subjects with normal WBC counts. VEIR in particular is able to
distinguish septic subjects, yielding values that are higher by approximately 2 μm for both neutrophils and monocytes, corresponding to a Cohen’s d larger than 2 for both cell types,
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Fig 3. (A, top panel) Histogram of WBC counts in healthy donors (n = 72), subjects with SIRS 2+ (n = 323), and subjects with sepsis (n = 78). (A,
bottom panel) Scatter plots of VEIR and Aspect Ratio in neutrophils and monocytes from the subset of healthy donors (n = 62), subjects with SIRS 2+
(n = 134) and subjects with sepsis (n = 13) that have normal WBC counts between 4 x 106 and 12 x 106 cells/mL. The lines on each graph indicate the
decision boundary and the margins for a linear Support Vector Machine classification algorithm that is able to separate subjects between septic and
non-septic using mean VEIR and mean AR features. (B) Scatter plots of AR and VEIR in neutrophils and monocytes from subjects with normal WBC
counts. The lines indicate the linear regression between Aspect Ratio or VEIR and cell count.
https://doi.org/10.1371/journal.pone.0246980.g003

showing a large effect size. These results further support that additional information is provided by AR and VEIR as compared to traditional cell counts.

Model performance
The performance of the ISI, which is produced by linearly transforming the prediction in the
log-odds space from the final model, was evaluated in a series of cross validation experiments.
As described more fully in Materials and Methods, only data from the high acuity cohort was
used to develop the final model, using an initial training set (n = 238), a sequestered testing set
(n = 69), and then the full training set (n = 307).
A first evaluation of model performance was conducted using a cross-validation framework
with the initial training set, resulting in an area under the receiving operating curve (AUC) of
0.92 (0.87–0.96; 95% CI). To further test generalizability, the model trained on the initial training set was tested on the sequestered testing set, resulting in an AUC of 0.90 (0.80–0.98; 95%
CI). The final model was then trained on the full training set with an AUC of 0.91 (0.87–0.95;
95% CI) (Fig 4A).
In a separate set of cross validation experiments, the high acuity cohort was randomly partitioned into three folds, where models were trained on data from 2/3 of the data (n = 205) and
tested on the remaining 1/3 (n = 102), using the same method used to create the final model.
AUC values derived for these models were 0.89 (0.82–0.95; 95% CI), 0.90 (0.79–0.98; 95% CI)
and 0.93 (0.86–0.98; 95% CI), which were close to the AUC of the final model of 0.91 (0.81–
0.96; 95% CI), as shown in S2 Fig. The high acuity cohort was also randomly partitioned 100
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Fig 4. (A) Receiver Operating Characteristic (ROC) curves showing the performance of the ISI as a diagnostic binary
classifier to distinguish septic vs. non-septic subjects for the initial training set (n = 238, adjudicated sepsis incidence of
25.2%), the sequestered testing set (n = 69, adjudicated sepsis incidence of 17.4%), and the full training set (n = 307,
sepsis incidence of 23.5%). Also shown are logistic distributions of ISI values for (B) the high acuity cohort (n = 307,
adjudicated sepsis incidence of 23.5%), (C) the low acuity cohort (n = 94, sepsis incidence of 6.4%), and (D) the cohort
of healthy donors (n = 72).
https://doi.org/10.1371/journal.pone.0246980.g004

times into 10 folds, where models were trained on 9/10 of the data and tested on the remaining
1/10 of the data. As shown in S3 Fig, the mean AUC from the repeated 10-fold partitions was
0.91, which again was close to the AUC found for the sequester set as well as the final model.
Taken together, these results indicate that the performance of the model was not the result of
overfitting, and would generalize well beyond the high acuity cohort.
Data from separate cohorts (low acuity and healthy population) with different incidence
rates of sepsis were evaluated to assess the generalizability of the model and estimate its
expected clinical performance. The data show that the ISI distinguished septic from non-septic
subjects in the high acuity cohort (Fig 4B), as well as the low acuity cohort (Fig 4C) and the
cohort of healthy donors (Fig 4D). In all three cohorts, septic subjects had higher ISI values
that were clearly distinct from lower ISI values of the non-septic subjects.
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In the high acuity cohort, 195 (63.5%) of subjects were in the Green Band, 53 (17.3%) in the
Yellow Band, and 59 (19.2%) in the Red Band. A negative predictive value for sepsis (NPV) of
95% (83–98, 95% CI) for subjects in the Green Band and a diagnostic odds ratio of 102 when
comparing those in Green and Red Bands was observed. Similar performance trends were
observed for the low acuity cohort. As expected, a higher proportion of subjects fell in the
Green Band (73, 77.7%), compared to 10 (10.6%) in the Yellow Band, and 11 (11.7%) in the
Red Band. The observed NPV was 100% (40–100, 95%CI) for subjects in the Green Band.
Note that the wide 95% CIs reported for the low acuity cohort is due to the low number of septic patients. All healthy donors had a low ISI value that fell within the Green Band. There were
no significant differences in baseline demographics (age, sex, and race) across interpretation
bands for any of the cohorts (S2 Table).

Clinical studies
Table 2 shows the diagnosis for subjects in the high acuity cohort as determined by retrospective physician adjudication, separated into those with high ISI (Red Band) and those with low
ISI (Green Band). The data show that not all subjects in the Red Band were adjudicated as having sepsis (right side of Table 2). However, nearly 90% of subjects in the Red Band had a diagnosis associated with activation of the immune system (i.e., either sepsis or a non-infectious
severe immune response). By contrast, only 5% of subjects in the Green Band were adjudicated
as septic (left side of Table 2), and the rest were diagnosed as having conditions not expected
to be associated with activation of the immune system.
Trends in the severity of illness across the ISI interpretation bands are shown in Fig 5. For
this analysis, the high acuity and low acuity cohorts were combined and subjects were evaluated by four measures, including SOFA score (maximum over 3 days), APACHE-II score,
number of hospital-free days, and admission to the ICU. Hospital-free days were calculated as
28 days less the in-hospital LOS, where in-hospital mortality leads to a value of zero. The data
show statistically significant differences between subjects in the Red Band, Yellow Band, and
Green Band for all four measures, indicating that the ISI interpretation bands stratify for severity of illness and use of hospital resources.
The potential clinical relevance of the ISI was further explored by Kaplan-Meier survival
analysis of all subjects in the high acuity cohort (n = 307) as well as the subpopulation of
Table 2. Diagnosis of subjects in the high acuity cohort separated into those with high ISI (Red Band) and those with low ISI (Green Band).
Green Band (ISI 0.1–5.4) N = 195

Red Band (ISI 6.8–10.0) N = 59

Congestive Heart Failure/ Chest Pain/Atrial
Fibrillation

54
(27.7%)

Sepsis

50
(84.7%)

Chronic Respiratory Disease/COPD

39
(20.0%)

Non-infectious Severe Immune Response (flare of Ulcerative Colitis, Rheumatoid Arthritis
Pericarditis, Sarcoidosis)

3 (5.1%)

Abdominal Pain/GI Bleed/Volume Depletion

19 (9.7%) Infection with Chronic/Direct Organ Dysfunction

2 (3.4%)

Complications of Diabetes

16 (8.2%) Cardiac Arrest/Emergency Heart Failure

2 (3.4%)

Infection without Organ Dysfunction

14 (7.2%) Other

2 (3.4%)

Alcohol/Substance Abuse

11 (5.6%)

Chronic Kidney Disease/ESRD

10 (5.1%)

Encephalopathy/seizures

10 (5.1%)

Sepsis

10 (5.1%)

Chronic liver Disease

4 (2.1%)

Direct Limb Injury/Fall

4 (2.1%)

Other

4 (2.1%)

https://doi.org/10.1371/journal.pone.0246980.t002
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Fig 5. Trends in severity of illness across ISI interpretation bands for subjects in the high and low acuity cohorts, as measured by (A) SOFA,
maximum over three days following ED presentation, (B) APACHE-II, (C) hospital free days for the subpopulation of subjects admitted to the
hospital, (D) Admission to the ICU. Hospital free days were defined as 28 days less the in-hospital length of stay, where in-hospital mortality leads to a
value of zero. Box plots: lines in the boxes, medians; the box ends, interquartile ranges (IQR); whiskers, 1.5x IQR; diamonds, outliers. Bar graphs: Bars,
percentages; error pars, 95% confidence intervals. p-values were obtained from an unpaired two-sample Welch’s t-test (except for hospital free days,
where the Mann–Whitney U was due to the non-normal distribution), with the null hypothesis that the mean of the two samples are equal. p-values
reported as � p < 0.05, �� p < 0.01, and ��� p < 0.001.
https://doi.org/10.1371/journal.pone.0246980.g005

subjects adjudicated as infected by independent physician review (n = 102). The data in Fig 6
show that the ISI interpretation band is correlated with survival probability. Specifically, subjects in the Red Band were clearly distinguished from those in the Green Band (p < 0.001, Fig
6A). Consistent with this result, among subjects adjudicated as infected, those in the Red Band
were clearly distinguished from those in the Green Band (p < 0.01, Fig 6B). The survival
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Fig 6. Kaplan-Meier survival stratified by ISI interpretation band for (A) all evaluable subjects (n = 307) and (B) a subpopulation of subjects
adjudicated as infected (n = 102) in the high acuity cohort. Plots were created with right-censoring, with the assumption that subjects discharged
from the ED or hospital survived � 30 days in the absence of evidence to the contrary (e.g., return to the ED, discharge to hospice, or other indication
in the electronic health record, which was reviewed after 30 days, that the subject died). Shading depicts 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0246980.g006

curves for the subpopulation of infected subjects is notable in that all of these subjects presented to the ED with two or more criteria for SIRS and at least one sign of potential organ
dysfunction. As such, the Kaplan-Meier analysis shown in Fig 6B reflects mortality from
sepsis.

Discussion
Early recognition and prompt treatment of sepsis is critical for reducing morbidity and mortality. Although time is of the essence, ED clinicians lack rapid, efficient tests to identify sepsis
among patients with signs of infection. In this study, we present the development and initial
validation of the ISI that may be useful as an aid for ED clinicians in the rapid and accurate
diagnosis of sepsis. The ISI’s high NPV may enable ED clinicians to quickly identify and treat
septic patients, while distinguishing non-septic patients for whom aggressive antibiotic therapy
and resuscitation may not be warranted, and where an alternate diagnosis should be
considered.
We developed the ISI using a technique that measures the biophysical properties of WBCs
as they are stretched through a microfluidic channel [10–12]. This technique enables the characterization of thousands of single cells in a matter of minutes, and provides information on
the host immune system that can be used to distinguish patients with sepsis [13]. By applying
this technique to a high acuity patient population in the ED context, we were able to define
specific metrics—the AR and VEIR—that are much more sensitive than measures such as cell
size or cell count in predicting severity of disease. Our final model incorporates AR and VEIR
to yield predictions on disease severity from which the ISI is derived. For ease of clinical interpretation, we divided the ISI into three interpretation bands of Green (0.1–5.4), Yellow (5.5–
6.7), and Red (6.8–10.0) that correspond to increasing disease severity. Importantly, the data
analysis, from raw video to ISI, is entirely automated, and does not require any human expert
judgment or intervention. The clinician is directly given the ISI and corresponding interpretation band for a sample.
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Our data show that the ISI interpretation bands correspond to the diagnosis established by
retrospective physician adjudication, with sepsis or a non-infectious severe immune response
diagnosed in nearly 90% of subjects in the Red Band but only 5% of subjects in the Green
Band (Table 2). The ISI interpretation bands accurately identified subjects with more severe illness and in greater need of hospital resources as measured by SOFA score (maximum over 3
days), APACHE-II score, number of hospital-free days, and admission to the ICU (Fig 5).
Moreover, the ISI interpretation bands clearly distinguished mortality risk in a high acuity
population where all subjects presented to the ED with two or more criteria for SIRS and at
least one sign of potential organ dysfunction (Fig 6A), and accurately identified patients with
infections severe enough to cause morbidity and mortality (Fig 6B).
The ISI is designed for use in the ED and offers a number of distinct advantages over other
approaches for sepsis diagnosis. The ISI can be measured from routinely collected blood samples and so there is no need for ED clinicians to order additional blood draws requiring specialized and expensive sample collection such as is needed for RNA profiling methods [18, 19].
The run-time is short, targeted to less than 10 minutes end-to-end, including sample processing and image analysis (with the prototype unit used in this study, approximately 30 minutes).
As such, ISI results can be available much sooner than other indicators of sepsis, enabling ED
clinicians to intervene and potentially mitigate subsequent organ dysfunction. Unlike
approaches reliant on electronic health records, the ISI does not require any patient or laboratory information. Another distinction is that the ISI can provide meaningful information at
the point of treatment in the ED, whereas other approaches for sepsis diagnosis are intended
for patient management in the ICU where clinical decisions identifying patients most at risk of
clinical deterioration have already been made [20, 21]. While some markers (e.g., lactate or Creactive protein) provide an indication that organ damage has occurred, the ISI measures the
activation of innate immunity that may lead to organ damage, thus providing an early warning. Lastly, because the test itself can be easily performed and interpreted, the ISI fits well
within the ED workflow and may help improve the quality and efficiency of care.
This study has several limitations. First, the ISI was developed and internally validated with
data from cohorts at two medical centers in Baton Rouge, which may limit the generalizability
of the findings. For example, while we expect the age and sex distribution of the studies to be
representative of what is expected of adults presenting to the ED across the US (when compared to data from the National ambulatory Medical Care Surveys collected by the Centers for
Disease Control and Prevention), the cohorts in this study included a predominance of White
and African American subjects and did not include significant numbers of subjects with Hispanic, Asian or other heritage. Additionally, the majority of subjects in the healthy study were
White, and the race distribution of this cohort differed from that of the high and low acuity
cohorts. Another limitation is that the study was not designed for longitudinal evaluation of
the ISI or for direct head-to-head comparisons of the ISI with currently available biomarkers.
Larger studies with different patient populations at multiple sites are currently underway to
externally validate the performance of the ISI and to assess the potential clinical utility of the
ISI in the ED context.
In conclusion, this study shows that the ISI has the potential to provide clinically actionable
performance in distinguishing potentially septic patients. The ISI identifies patients with infections severe enough to cause morbidity and mortality, and can help ED clinicians in quickly
recognizing sepsis and prioritizing hospital resources to care for those most at risk for clinical
deterioration and death. Like other indicators of the host immune response, the ISI is pathogen agnostic and provides valuable information regardless of whether sepsis is caused by bacterial or viral infection. With a short turn-around time and no requirements for additional
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patient or laboratory data, the ISI is particularly well suited to aid ED clinicians in rapidly diagnosing sepsis.
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